• Home
• Reports
• Companies

• Partnering Search
• Profiling
• Deal Negotiation

• Out-licensing
• In-licensing
• Services

• PL Intelligence
• Deals review
• Industry news

• Press releases
• Events
• Newsletter

Latest: Watch here for details of new products and services.

Pharmalicensing
is a division of
UTEK Europe Ltd

— GOTHENBURG, Sweden, May 15

GOTHENBURG, Sweden, May 15 /PRNewswire/ -- Albireo, a pharmaceutical company focusing on the development of therapeutics for gastrointestinal diseases, announced today the appointment of Hans Graffner, M.D., Ph.D, as Chief Medical Officer (CMO).

Dr. Graffner will oversee the clinical development programs at Albireo with initial focus on the lead program A3309, a therapeutic with a novel mechanism of action targeting the treatment of patients with chronic constipation.

Dr. Graffner comes to Albireo with over 12 years experience of leading clinical development programs in the pharmaceutical industry. Most recently, Dr. Graffner was the Senior Medical Director at Merck Serono, leading clinical development of products mainly in the areas of autoimmune diseases, including inflammatory bowel diseases. Dr. Graffner has an impressive track record of success, bringing Entocort (budesonide) and Colazide (balsalazide) through registration and bringing Nexium to market at AstraZeneca.

Dr. David Chiswell, Executive Chairman of the Albireo Board of Directors, said: "We are delighted to have been able to attract Hans to Albireo as our CMO. His extensive and impressive experience in bringing products from early clinical development to the market within the gastrointestinal area will be of great value for the clinical development of our lead program A3309 as well as future development programs."

About Albireo

Albireo is a Swedish biotechnology company with broad experience in the GI area and a pipeline of programmes for underserved markets. Spun off from AstraZeneca in February 2008, the Albireo team has extensive links to industry and academia, as well as key scientific and clinical communities. Albireo is focused on developing novel therapies that address unmet medical needs in the GI area. Albireo is based in Gothenburg, Sweden. For more information please visit http://www.albireopharma.com

Get the Flash Player to see this rotator.

Press releases: Pharmalicensing current industry press releases.

Products:	Partnering Search	Company Profiling	Deal Negotiation	PL Intelligence	Reports	Comparision
In-licensing:	Latest records	Industry Sector	Therapeutic Target	Search	Profile your company	Pharma partnering
Out-licensing:	Latest records	Industry Sector	Therapeutic Target	Search	Profile your company	Pharma partnering
Companies:	Profiled companies	Industry Sector	Therapeutic Target	Geographic Location	Search	Add your company
Reports:	Biotechnology	Business Development	Management	Market & Sales	Medical Devices	Pharmaceuticals
Jobs:	Pharmaceutical jobs	Browse jobs	Search for jobs	Create your CV	Employer profiles	Post your jobs
Forums:	Talk to an expert	Industry Gossip	Business Development	What's new	Reports	Services
News:	Deals & Alliances	Development	Financial Results	Financings	Intellectual Property	Regulatory
Events:	Pharma events	Calendar	Organizers	Featured events	Search
Articles:	Business Development	Technologies	Events	Legal and regulatory	Therapeutic
Deals:	Industry Sector	Therapeutic Target	Deals Date	Search	Reports	Press releases
About us:	Our Audience	Case Studies	Newsletter	Careers	FAQ	Contact us